Medesis Pharma is a clinical development stage biopharmaceutical Company that is engaged through its unique and proven drug delivery technology – Aonys® – in the development of orally administered molecule drug candidates to expand their therapeutic usefulness to address major unmet medical needs. Medesis Pharma is listed on the French stock exchange of Euronext Growth Paris.
Medesis Pharma is currently applying its Aonys® technology to:
Medesis Pharma’s technology is also being used for collaborative research programs focused on oncology (customized cancer treatment) and radiotherapy (protection of healthy tissue), as well as a collaborative program with the company TRANSGENE.
4 programs in Phase II clinical trials in 2021
NanosiRNA® COVID-19: specific antiviral treatment Medesis Pharma has a microemulsion technology that enables it to deliver these non-modified native siRNAs directly into the cytoplasm of all the organism’s cells via the HDL lipoprotein receptors, crossing the blood–brain barrier (BBB) after a non-invasive oral administration.
Medesis Pharma is developing a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 – NanoManganese®). Preclinical trials have been carried out with the French Armed Forces Biomedical Research Institute (IRBA). (Study reports available) A series of studies have been
TRANSGENE (Euronext Paris: TNG), a biotechnology company designing and developing virus-based immunotherapies against cancers and infectious diseases, has signed a collaborative research agreement with Medesis Pharma with exclusive license options to co-develop an intracellular protein inhibitor that decreases the efficacy
Medesis Pharma is developing a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 – NanoManganese®). Preclinical trials have been carried out with the French Armed Forces Biomedical Research Institute (IRBA). (Study reports available) A series of studies have been conducted
